Centor/McIsaac Criteria Calculator — Strep Pharyngitis

About

The Centor criteria were originally described by Robert M. Centor in 1981 as a 4-point clinical scoring system for adult patients with acute pharyngitis to predict the likelihood of group A streptococcal infection. The criteria included fever (temperature >38°C), absence of cough, tonsillar exudates, and tender anterior cervical lymphadenopathy. In 1998, Dr. Richard McIsaac validated and modified the criteria to include age-based adjustments, adding 1 point for patients aged 3-14 years and subtracting 1 point for patients aged 45 years or older. This modification improved the criteria's diagnostic accuracy across all age groups, extending its applicability from adults only to both adult and pediatric populations. The McIsaac modification is now the most widely used version in clinical practice. The criteria are recommended by the Infectious Diseases Society of America (IDSA), the American Academy of Family Physicians (AAFP), and the National Institute for Health and Care Excellence (NICE) as a clinical decision support tool to guide testing and treatment decisions. The score ranges from 0 to 5, with higher scores correlating with increased probability of positive throat culture for GAS (from approximately 1% at score 0 to 51-53% at score 4-5). The clinical rationale is to accurately identify patients who benefit from antibiotic therapy while minimizing unnecessary antibiotic prescriptions, thereby reducing antimicrobial resistance.

Formula

Score = Fever (>38°C) + Absent cough + Tonsillar exudates + Tender anterior cervical LAD + Age adjustment

The McIsaac-modified Centor score is calculated by assigning 1 point for each of four clinical criteria present: (1) documented or reported fever with temperature >38°C (100.4°F), (2) absence of cough (cough suggests viral etiology and reduces likelihood of GAS), (3) tonsillar exudates or swelling visualized on oropharyngeal examination (white or yellow patches on tonsils), and (4) tender anterior cervical lymphadenopathy (enlarged, tender lymph nodes in the anterior neck triangle). An age adjustment is then applied: if age is 3-14 years, add 1 point (children have higher GAS prevalence); if age is 45 years or older, subtract 1 point (adults over 45 have lower GAS prevalence and higher risk of complications). The total score ranges from 0 to 5. Score 0-1: very low probability (1-10%), no testing or antibiotics indicated. Score 2-3: moderate probability (11-35%), testing with rapid antigen detection test or throat culture recommended, with antibiotics guided by results. Score 4-5: high probability (51-53%), testing recommended if available and empiric antibiotics may be appropriate.

Score Interpretation

The Centor/McIsaac criteria are one of the most widely validated and implemented clinical prediction rules in ambulatory medicine. Their primary clinical significance lies in reducing inappropriate antibiotic prescribing for acute pharyngitis, a condition accounting for over 15 million clinic visits annually in the United States alone. Before the widespread adoption of these criteria, up to 70% of patients with acute sore throat received antibiotics despite viral etiologies being responsible for the majority (80-90%) of cases. The criteria enable risk stratification that closely correlates with GAS recovery rates on throat culture: 1-2.5% at score 0, 5-10% at score 1, 11-17% at score 2, 28-35% at score 3, and 51-53% at score 4-5. A systematic review and meta-analysis of 24 studies (n=41,246 patients) published in JAMA Internal Medicine (2016) found that the pooled prevalence of GAS pharyngitis ranged from 1% at Centor score 0 to 52% at score 4-5. The IDSA guidelines recommend that patients with Centor score 0-2 should not receive antibiotics or testing, while score 3-4 should prompt testing, with antibiotics reserved for positive results. McIsaac's original validation study (JAMA, 1998) of 621 adults and children demonstrated a reduction in antibiotic prescribing from 62% to 26% when the criteria were applied. The criteria perform best in high-prevalence settings (winter/early spring) and in patients presenting within 3 days of symptom onset.

Reference Ranges